Myeloma Canada Says New Data At This Year’s Annual American Society of Hematology Meeting Offers A New Standard Of Care For Newly Diagnosed Multiple Myeloma Patients
12/10/2013 6:54:56 AM
Findings from a new study show continuous treatment with oral Revlimid® (lenalidomide) plus low-dose dexamethasone (Rd) improves survival and other measures of efficacy, compared to a standard of care for newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The findings are from the largest phase III global registration study ever conducted in newly diagnosed myeloma, including four Canadian centres, and were presented at the American Society of Hematology meeting in New Orleans, Louisiana, USA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by